Tag: parsaclisib
Innovent Biologics begins parsaclisib phase 2 trial in follicular lymphoma
Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and selective PI3Kδ inhibitor in follicular lymphoma (FL). ... Read More
Incyte, Innovent announce collaboration for three cancer drugs in China
US pharma company Incyte and Chinese biopharma company Innovent Biologics through their respective subsidiaries have entered into a deal worth up to $391.5 million for ... Read More